APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multiple Sclerosis Therapeutics Market Outlook and Growth Opportunities 2026

2 January 2026198 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis Therapeutics Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis Therapeutics Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multiple Sclerosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multiple Sclerosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Sclerosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multiple Sclerosis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multiple Sclerosis Therapeutics market include Biogen Idec, Sanofi Genzyme, Teva Pharmaceuticals, AbbVie, Bayer, Pfizer, Merck and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Multiple Sclerosis Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multiple Sclerosis Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multiple Sclerosis Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Multiple Sclerosis Therapeutics market.

Multiple Sclerosis Therapeutics Segment by Company

Biogen Idec

Sanofi Genzyme

Teva Pharmaceuticals

AbbVie

Bayer

Pfizer

Merck

Novartis

Multiple Sclerosis Therapeutics Segment by Type

Beta Interferon

Monoclonal Antibodies

Antineoplastic Agents

Corticosteroids

Others

Multiple Sclerosis Therapeutics Segment by Application

Hospital Pharmacies

Retail Pharmacies

e-Commerce

Multiple Sclerosis Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Multiple Sclerosis Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Multiple Sclerosis Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Multiple Sclerosis Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Multiple Sclerosis Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multiple Sclerosis Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Multiple Sclerosis Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multiple Sclerosis Therapeutics industry.

Chapter 3: Detailed analysis of Multiple Sclerosis Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Multiple Sclerosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Multiple Sclerosis Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multiple Sclerosis Therapeutics Industry Trends Table 2. Multiple Sclerosis Therapeutics Industry Drivers Table 3. Multiple Sclerosis Therapeutics Industry Opportunities and Challenges Table 4. Multiple Sclerosis Therapeutics Industry Restraints Table 5. Global Multiple Sclerosis Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multiple Sclerosis Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Multiple Sclerosis Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Multiple Sclerosis Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Multiple Sclerosis Therapeutics Company, Product Type & Application Table 10. Global Multiple Sclerosis Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Multiple Sclerosis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Beta Interferon Table 15. Significant Companies of Monoclonal Antibodies Table 16. Significant Companies of Antineoplastic Agents Table 17. Significant Companies of Corticosteroids Table 18. Significant Companies of Others Table 19. Global Multiple Sclerosis Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Multiple Sclerosis Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Multiple Sclerosis Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Multiple Sclerosis Therapeutics Sales Value Share by Type (2021-2026) Table 23. Global Multiple Sclerosis Therapeutics Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Pharmacies Table 25. Significant Companies of Retail Pharmacies Table 26. Significant Companies of e-Commerce Table 27. Global Multiple Sclerosis Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Multiple Sclerosis Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Multiple Sclerosis Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Multiple Sclerosis Therapeutics Sales Value Share by Application (2021-2026) Table 31. Global Multiple Sclerosis Therapeutics Sales Value Share by Application (2027-2032) Table 32. Global Multiple Sclerosis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Multiple Sclerosis Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Multiple Sclerosis Therapeutics Sales Value Share by Region (2021-2026) Table 35. Global Multiple Sclerosis Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Multiple Sclerosis Therapeutics Sales Value Share by Region (2027-2032) Table 37. Global Multiple Sclerosis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Multiple Sclerosis Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Multiple Sclerosis Therapeutics Sales Value Market Share by Country (2021-2026) Table 40. Global Multiple Sclerosis Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Multiple Sclerosis Therapeutics Sales Value Market Share by Country (2027-2032) Table 42. Biogen Idec Company Information Table 43. Biogen Idec Business Overview Table 44. Biogen Idec Multiple Sclerosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Biogen Idec Multiple Sclerosis Therapeutics Product Portfolio Table 46. Biogen Idec Recent Development Table 47. Sanofi Genzyme Company Information Table 48. Sanofi Genzyme Business Overview Table 49. Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Sanofi Genzyme Multiple Sclerosis Therapeutics Product Portfolio Table 51. Sanofi Genzyme Recent Development Table 52. Teva Pharmaceuticals Company Information Table 53. Teva Pharmaceuticals Business Overview Table 54. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Portfolio Table 56. Teva Pharmaceuticals Recent Development Table 57. AbbVie Company Information Table 58. AbbVie Business Overview Table 59. AbbVie Multiple Sclerosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. AbbVie Multiple Sclerosis Therapeutics Product Portfolio Table 61. AbbVie Recent Development Table 62. Bayer Company Information Table 63. Bayer Business Overview Table 64. Bayer Multiple Sclerosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Bayer Multiple Sclerosis Therapeutics Product Portfolio Table 66. Bayer Recent Development Table 67. Pfizer Company Information Table 68. Pfizer Business Overview Table 69. Pfizer Multiple Sclerosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Pfizer Multiple Sclerosis Therapeutics Product Portfolio Table 71. Pfizer Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Multiple Sclerosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck Multiple Sclerosis Therapeutics Product Portfolio Table 76. Merck Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Multiple Sclerosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Novartis Multiple Sclerosis Therapeutics Product Portfolio Table 81. Novartis Recent Development Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. Multiple Sclerosis Therapeutics Product Image Figure 2. Global Multiple Sclerosis Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Multiple Sclerosis Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Beta Interferon Image Figure 8. Monoclonal Antibodies Image Figure 9. Antineoplastic Agents Image Figure 10. Corticosteroids Image Figure 11. Others Image Figure 12. Global Multiple Sclerosis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Multiple Sclerosis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Multiple Sclerosis Therapeutics Sales Value Share by Type (2021-2032) Figure 15. Hospital Pharmacies Image Figure 16. Retail Pharmacies Image Figure 17. e-Commerce Image Figure 18. Global Multiple Sclerosis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Multiple Sclerosis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Multiple Sclerosis Therapeutics Sales Value Share by Application (2021-2032) Figure 21. Global Multiple Sclerosis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Multiple Sclerosis Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Multiple Sclerosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. North America Multiple Sclerosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Multiple Sclerosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Multiple Sclerosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Multiple Sclerosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Multiple Sclerosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Multiple Sclerosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. South America Multiple Sclerosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Multiple Sclerosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Multiple Sclerosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Beta Interferon
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Corticosteroids
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
Companies covered
  • Biogen Idec
  • Sanofi Genzyme
  • Teva Pharmaceuticals
  • AbbVie
  • Bayer
  • Pfizer
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multiple Sclerosis Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multiple Sclerosis Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Multiple Sclerosis Therapeutics Market Dynamics
  1. 2.1 Multiple Sclerosis Therapeutics Industry Trends
  2. 2.2 Multiple Sclerosis Therapeutics Industry Drivers
  3. 2.3 Multiple Sclerosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis Therapeutics Industry Restraints
3 Multiple Sclerosis Therapeutics Market by Company
  1. 3.1 Global Multiple Sclerosis Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Multiple Sclerosis Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Multiple Sclerosis Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Multiple Sclerosis Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Multiple Sclerosis Therapeutics Company Product Type and Application
  6. 3.6 Global Multiple Sclerosis Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Multiple Sclerosis Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Multiple Sclerosis Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Multiple Sclerosis Therapeutics Market by Type
  1. 4.1 Multiple Sclerosis Therapeutics Type Introduction
  2. 4.1.1 Beta Interferon
  3. 4.1.2 Monoclonal Antibodies
  4. 4.1.3 Antineoplastic Agents
  5. 4.1.4 Corticosteroids
  6. 4.1.5 Others
  7. 4.2 Global Multiple Sclerosis Therapeutics Sales Value by Type
  8. 4.2.1 Global Multiple Sclerosis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Multiple Sclerosis Therapeutics Sales Value by Type (2021-2032)
  10. 4.2.3 Global Multiple Sclerosis Therapeutics Sales Value Share by Type (2021-2032)
5 Multiple Sclerosis Therapeutics Market by Application
  1. 5.1 Multiple Sclerosis Therapeutics Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 e-Commerce
  5. 5.2 Global Multiple Sclerosis Therapeutics Sales Value by Application
  6. 5.2.1 Global Multiple Sclerosis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Multiple Sclerosis Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Multiple Sclerosis Therapeutics Sales Value Share by Application (2021-2032)
6 Multiple Sclerosis Therapeutics Regional Value Analysis
  1. 6.1 Global Multiple Sclerosis Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multiple Sclerosis Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Multiple Sclerosis Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Multiple Sclerosis Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multiple Sclerosis Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Multiple Sclerosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Multiple Sclerosis Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Multiple Sclerosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Multiple Sclerosis Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Multiple Sclerosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Multiple Sclerosis Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Multiple Sclerosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Multiple Sclerosis Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Multiple Sclerosis Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Multiple Sclerosis Therapeutics Country-level Value Analysis
  1. 7.1 Global Multiple Sclerosis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multiple Sclerosis Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Multiple Sclerosis Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Multiple Sclerosis Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Multiple Sclerosis Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Multiple Sclerosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Multiple Sclerosis Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen Idec
  2. 8.1.1 Biogen Idec Company Information
  3. 8.1.2 Biogen Idec Business Overview
  4. 8.1.3 Biogen Idec Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Idec Multiple Sclerosis Therapeutics Product Portfolio
  6. 8.1.5 Biogen Idec Recent Developments
  7. 8.2 Sanofi Genzyme
  8. 8.2.1 Sanofi Genzyme Company Information
  9. 8.2.2 Sanofi Genzyme Business Overview
  10. 8.2.3 Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Genzyme Multiple Sclerosis Therapeutics Product Portfolio
  12. 8.2.5 Sanofi Genzyme Recent Developments
  13. 8.3 Teva Pharmaceuticals
  14. 8.3.1 Teva Pharmaceuticals Company Information
  15. 8.3.2 Teva Pharmaceuticals Business Overview
  16. 8.3.3 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Portfolio
  18. 8.3.5 Teva Pharmaceuticals Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Multiple Sclerosis Therapeutics Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Multiple Sclerosis Therapeutics Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Multiple Sclerosis Therapeutics Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Multiple Sclerosis Therapeutics Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Multiple Sclerosis Therapeutics Product Portfolio
  48. 8.8.5 Novartis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst